Liraglutide (LRGT), specifically, is a GLP-1 receptor agonist that crosses the blood-brain barrier (Perry and Greig, 2005) and is currently being tested on patients with AD in the Evaluating Liraglutide in Alzheimer’s Disease (ELAD) clinical trial (NCT01843075) (Femminella et al., 2019). This evidence concerns the gene GLP1R and Alzheimer disease.